Logotype for Dexcom Inc

Dexcom (DXCM) Q4 2022 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Dexcom Inc

Q4 2022 earnings summary

4 Nov, 2026

Executive summary

  • Revenue grew 19% to $2.91B in 2022, with annual new-customer additions reaching a record; the year ended with an estimated 1.7M global CGM users.

  • G7 received CE Mark and FDA clearance, while expansion of Dexcom ONE and proposed Medicare coverage for more people with type 2 diabetes broadened access opportunities.

Financial highlights

  • Revenue was $2,909.8M, up 19% YoY; gross profit rose 12% to $1,883.1M, while operating income increased 47% to $391.2M.

  • Net income increased 57% to $341.2M; diluted EPS was $0.82 versus $0.53 in 2021, on an adjusted comparative basis.

  • Operating cash flow rose 51% to $669.5M; cash, cash equivalents and short-term marketable securities totaled $2.46B at year-end.

  • Cost of sales rose 34% to $1,026.7M; gross margin fell to 64.7% from 68.6%, primarily due to price, product and channel mix, and FX impacts.

  • 2022 SG&A included a $23.0M noncash impairment charge; 2021 included an $87.1M Verily regulatory milestone R&D charge.

Outlook and guidance

  • Priorities for 2023 include the continued G7 and Dexcom ONE rollouts, expanding global CGM access, and serving new populations, including U.S. customers with type 2 diabetes on basal insulin.

  • Manufacturing scale-up is underway for G7; production at the first international facility in Malaysia was expected to begin in 2023.

  • A CMS coverage proposal for people with type 2 diabetes using basal insulin was slated to take effect in April 2023, potentially broadening access to an estimated 3M U.S. people in that group.

  • Existing cash, short-term investments and expected operating cash flows were considered sufficient for core operations and anticipated liquidity needs for at least the next 12 months.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Dexcom